Abstract
Most of the opioids used in clinical practice exert their effects through μ opioid receptors. Yet, subtle but important pharmacological differences have been observed among the μ opioids. Their potency, effectiveness, and adverse effects can vary unpredictably among patients. These clinical differences among the μ opioids strongly argue against a single receptor mediating their actions. The cloning of the μ opioid receptor has greatly enhanced our understanding of the complexity of this system and has provided possible mechanisms to explain these observations. A single μ opioid receptor gene has been identified, but we now know that it generates a multitude of different μ opioid receptor subtypes through a mechanism commonly used to enhance protein diversity, alternative splicing. Early studies identified a number of splice variants involving the tip of the C-terminus. This region of the receptor is far away from the binding pocket, explaining why these variants still exhibit the same selectivity for μ opioids. However, the differences in structure at the C-terminus influence the activation patterns of the μ opioids. In addition, a second series of variants has been isolated that involves alternative splicing at the N-terminus. Together, these sets of μ opioid receptor splice variants may help explain the clinical variability of the μ drugs among patients and provide insights into why it is so important to individualize therapy for every patient in pain.

This publication has 35 references indexed in Scilit: